LMR Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.7M Buy
+200,000
New +$5.32M 0.02% 636
2026
Q1
– Sell
-500,000
Closed -$12.4M – 1771
2025
Q4
$12.4M Hold
500,000
– – 0.02% 305
2025
Q3
$12.7M Hold
500,000
– – 0.06% 259
2025
Q2
$12.1M Hold
500,000
– – 0.09% 238
2025
Q1
$12.7M Hold
500,000
– – 0.12% 195
2024
Q4
$13.3M Buy
500,000
+375,000
+300% +$10.2M 0.11% 182
2024
Q3
$3.62M Buy
+125,000
New +$3.65M 0.03% 442
2023
Q4
– Sell
-498,300
Closed -$16.5M – 1097
2023
Q3
$16.5M Sell
498,300
-50,000
-9% -$1.77M 0.19% 125
2023
Q2
$20.1M Buy
+548,300
New +$21.3M 0.22% 102
2022
Q2
– Sell
-1,227,100
Closed -$63.5M – 1418
2022
Q1
$63.5M Buy
+1,227,100
New +$63.7M 0.74% 16

Other funds holding PFE

LMR Partners's PFE Position: Q3 2026 in Review

LMR Partners sold out of Pfizer (PFE) in Q3 2026, closing a stake of 260,990 shares — an estimated $6.94M sold.

LMR Partners first reported a position in PFE in Q4 2015 and held it in 18 quarters. The position peaked at $16.9M in Q4 2024. 2,908 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • LMR Partners reported no remaining Pfizer position as of Q3 2026 after selling out during the quarter.
  • LMR Partners sold 260,990 Pfizer shares in Q3 2026, an estimated $6.94M.
  • LMR Partners first reported a position in Pfizer in Q4 2015 and held it in 18 quarters.
  • LMR Partners's Pfizer position peaked at $16.9M in Q4 2024.
  • 2,908 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.